Health

Results: 4753-4764 of 5143

Zymfentra® (Photo: Celltrion)

Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger

Business Wire logo

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

Nanoform grant Global STARMAP® AI License to AstraZeneca

PR Newswire associated0

Prostate Cancer Diagnosis Just Got Easier with CE Mark Certification of Lucida Medical's New AI Software

Business Wire logo

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

GlobeNewswire associated0

LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub

PR Newswire associated0

Velico Medical launches Blood Center Education Program with South Texas Blood & Tissue

CORRECTION: Bioretec Ltd's Board of Directors has decided on a new option program 2023-1

PR Newswire associated0

Cancer Prevention Scholars and Climate Crisis Experts from Korea, US and Japan Come Together, iCOOP KOREA Holds the '2023 International Symposium'

Business Wire logo

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years

Bioretec Ltd's Board of Directors has decided on a new option program 2023-1